Phase 2Not yet recruiting
Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study
- Sponsor
- AIDS Malignancy Consortium (Research network)
- Enrolment
- 43 planned
- Conditions
- Adult Burkitt Lymphoma
- Interventions
- Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Cyclophosphamide; Doxorubicin; Echocardiography Test; Epcoritamab; Etoposide; Magnetic Resonance Imaging; Multigated Acquisition Scan; Positron Emission Tomography
- Ages
- adults, older adults
- Registry
- NCT07662928
From the registry
This phase II trial studies how well epcoritamab works in combination with the chemotherapy regimen dose adjusted etoposide, prednisone, Oncovin (vincristine), cyclophosphamide, hydroxydaunorubicin-rituximab (DA-EPOCH-R) in treating patients with high risk Burkitt lymphoma. Epcoritamab binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Epcoritamab is a type of bispecific T-cell engager. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response.…
Primary outcomes
- Proportion of participants who complete at least Cycle 3 among 10 participants (Feasibility)
- Overall survival